Post‐Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System
International Journal of Dermatology · 2026-04 · 65 (4) · 825-827
DOI: 10.1111/ijd.70082 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Dermatology, online erschienen am 24.09.2025. Verfasst von Tung S Tran und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hanoi Medical University, Hanoi, Vietnam. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 4 Literaturangaben.
Abstract (Originalsprache)
The authors declare no conflicts of interest. Data supporting this study are available upon reasonable request to the corresponding author.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hanoi Medical University, Hanoi, Vietnam.
- National Hospital of Dermatology and Venereology, Hanoi, Vietnam.
- Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.
- Bassett Medical Center, Cooperstown, New York, USA.
ORCID-Profile: Tung S Tran
Zitieren
APA
Tran, T. S., Le, D. V., Jacobs, J. C., Nguyen, T. M., Wetter, D. A., & Nguyen, G. H. (2026). Post‐Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System. International Journal of Dermatology, 65(4), 825-827. https://doi.org/10.1111/ijd.70082
Vancouver
Tran TS, Le DV, Jacobs JC, Nguyen TM, Wetter DA, Nguyen GH. Post‐Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System. International Journal of Dermatology. 2026;65(4):825-827. doi:10.1111/ijd.70082
BibTeX
@article{Tran2026,
author = {Tran, Tung S and Le, Duc V and Jacobs, Jena C and Nguyen, Trang M and Wetter, David A and Nguyen, Giang H},
title = {Post‐Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System},
journal = {International Journal of Dermatology},
year = {2026},
volume = {65},
number = {4},
pages = {825--827},
doi = {10.1111/ijd.70082}
}
EUVIMED